Literature DB >> 12480699

Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire.

Kathleen N Potter1, Jenny Orchard, Eustacia Critchley, C Ian Mockridge, Annette Jose, Freda K Stevenson.   

Abstract

Chronic lymphocytic leukemia (CLL) comprises 2 subsets, distinguished by expression of unmutated or mutated V(H) genes, with the former having a worse prognosis. Biased usage of the V1-69 gene is found in unmutated cases and is combined with selected D gene segments and J(H)6. It is controversial whether this is a CLL-associated feature or mirrors the normal B-cell pattern. Since CLL is a disease of the elderly, where changes in the B-cell repertoire may occur, we have analyzed V1-69 usage in the elderly (older than 75 years) population. Using monoclonal antibody (MoAb) G6, specific for 51p1-related V1-69 alleles, we found no increased expression with age. In 51p1-encoded immunoglobulin M (IgM), complementarity-determining region 3 (CDR3) length and frequency of D and J(H) genes were similar to those in the healthy young and distinct from those in CLL. These findings support the concept that CLL arises from B cells driven by antigen/superantigen and is not a stochastic event in the elderly B-cell population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12480699     DOI: 10.1182/blood-2002-08-2432

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia.

Authors:  Fabio Ghiotto; Franco Fais; Angelo Valetto; Emilia Albesiano; Shiori Hashimoto; Mariella Dono; Hideyuki Ikematsu; Steven L Allen; Jonathan Kolitz; Kanti R Rai; Marco Nardini; Anna Tramontano; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.

Authors:  George F Widhopf; Craig J Goldberg; Traci L Toy; Laura Z Rassenti; William G Wierda; John C Byrd; Michael J Keating; John G Gribben; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2007-08-03       Impact factor: 22.113

Review 3.  Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells.

Authors:  K Hayakawa; A M Formica; M J Colombo; S A Shinton; J Brill-Dashoff; H C Morse Iii; Y-S Li; R R Hardy
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

5.  Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL.

Authors:  De-Kuan Chang; Vinodh B Kurella; Subhabrata Biswas; Yuval Avnir; Jianhua Sui; Xueqian Wang; Jiusong Sun; Yanyan Wang; Madhura Panditrao; Eric Peterson; Aimee Tallarico; Stacey Fernandes; Margaret Goodall; Quan Zhu; Jennifer R Brown; Roy Jefferis; Wayne A Marasco
Journal:  MAbs       Date:  2016-03-10       Impact factor: 5.857

6.  Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen.

Authors:  Christoph Steininger; George F Widhopf; Emanuela M Ghia; Christopher S Morello; Katrina Vanura; Rebecca Sanders; Deborah Spector; Don Guiney; Ulrich Jäger; Thomas J Kipps
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

7.  IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group.

Authors:  I Kryachok; I Abramenko; N Bilous; A Chumak; Z Martina; I Filonenko
Journal:  Med Oncol       Date:  2011-03-04       Impact factor: 3.064

Review 8.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

9.  Ig V region restrictions in human chronic lymphocytic leukemia suggest some cases have a common origin.

Authors:  Grant R Kolar; J Donald Capra
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

10.  Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.

Authors:  Renee C Tschumper; Susan M Geyer; Megan E Campbell; Neil E Kay; Tait D Shanafelt; Clive S Zent; Grzegorz S Nowakowski; Timothy G Call; Gordon W Dewald; Diane F Jelinek
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.